A-PVP

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcThe prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland.
3. 2026-09-24srcCharacterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method.
4. 2026-09-24srcNeuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs
5. 2026-09-24srcSelf-administration and behavioral economics of second-generation synthetic cathinones in male rats.
6. 2026-09-24srcEffects of the new generation α-pyrrolidinophenones on spontaneous locomotor activities in mice, and on extracellular dopamine and serotonin levels in the mouse striatum.
7. 2026-09-24srcA review of synthetic cathinones emerging in recent years (2019–2022).
8. 2026-09-24srcStructural and functional perspectives on interactions between synthetic cathinones and monoamine transporters.
9. 2026-09-24srcPsychoactive 'bath salts' intoxication with methylenedioxypyrovalerone
10. 2026-09-24srcSynthetic cathinone self-administration in female rats modulates neurotransmitter levels in addiction-related brain regions.
11. 2026-09-24srcEffects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats.
12. 2026-09-24srcFindings of synthetic cathinones in post-mortem toxicology.
13. 2026-09-24srcSynthetic cathinones (bath salts)
14. 2026-09-24srcNew psychoactive versus conventional stimulants - a ten-year review of casework in Hungary.
15. 2026-09-24srcSex differences in inflammatory cytokine levels following synthetic cathinone self-administration in rats.
16. 2026-09-24srcRelative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats.
17. 2026-09-24srcNeuroadaptive changes and behavioral effects after a sensitization regime of MDPV.
18. 2026-09-24srcRole of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones.
19. 2026-09-24srcSex differences in α-pyrrolidinopentiophenone (α-PVP)-induced taste avoidance, place preference, hyperthermia and locomotor activity in rats.
20. 2026-09-24srcEthanol pre-exposure differentially impacts the rewarding and aversive effects of α-pyrrolidinopentiophenone (α-PVP).
21. 2026-09-24srcConditioned place preference with low dose mixtures of α-pyrrolidinopentiophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats.
22. 2026-09-24srcAlpha pyrrolidinovalerophenone (α-PVP) administration impairs spatial learning and memory in rats through brain mitochondrial dysfunction.
23. 2026-09-24srcMeasuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay.
24. 2026-09-24srcStructural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters.
25. 2026-09-24srcThe abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter.
26. 2026-09-24srcToxicological Analysis of Cases of Mixed Poisonings with Synthetic Cathinones and Other Drugs of Abuse.
27. 2026-09-24srcTesting for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine.
28. 2026-09-24srcCocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.
29. 2026-09-24srcStereoselective neurochemical, behavioral, and cardiovascular effects of α-pyrrolidinovalerophenone enantiomers in male rats.
30. 2026-09-24srcEarly and Mid-Term Disposition of α-PVP and its unknown Metabolites in Urine and Oral Fluid Through a Multi-Analytical Hyphenated Approach Following a Single Non-Controlled Administration to Healthy Volunteers.
31. 2026-09-24srcRisk factors for the development of psychotic disorders associated with synthetic cathinones usage.
32. 2026-09-24srcPharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.
33. 2026-09-24srcAlpha-PVP induces the rewarding effect via activating dopaminergic neuron.
34. 2026-09-24srcHazard Characterization of Synthetic Cathinones Using Viability, Monoamine Reuptake, and Neuronal Activity Assays
35. 2026-09-24srcAcute pharmacological effects of α-PVP in humans: a naturalistic observational study.
36. 2026-09-24srcMolecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts.
37. 2026-09-24srcFlakka: New Dangerous Synthetic Cathinone on the Drug Scene.
38. 2026-09-24srcα-PVP placed in Schedule I (US DEA)
39. 2026-09-24srcEU Council Decision on control measures for α-PVP
40. 2026-09-04issueIssued emergency
41. 2026-09-04issueIssued info_card
42. 2026-09-04issueIssued notice
43. 2026-06-04proposal49 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
44. 2026-06-04publicationPublication — backfill
45. 2026-04-26revisionRevision 1
46. 2026-04-26absenceSearched ClinicalTrials.gov for "alpha-PVP pyrrolidinopentiophenone stimulant" — no results
47. 2026-04-26genGeneration — pipeline-v5 · with 2 morepipeline-v5
48. 2026-04-26rungeneration run

The same entries, as forms: six forms.